ADMA Biologics Inc

ADMA remains rangebound in the lower half of its $8.50–$10.50 corridor with a medium-term bearish bias under declining moving averages. Short-term price sits marginally below the 9- and 20-day EMAs with repeated failures near the 9.60 resistance, favoring sell-side execution on any rally. Given the lack of bullish momentum and presence of distribution characteristics, we recommend selling now on strength around the EMA zone.

• ↑Ascentive drove total revenue to $124.4M (+2% YoY) with 24% growth
• ↑Gross margin rose to 69% (from 55%), and adjusted EBITDA climbed 22% to $61.8M
• ↓Increased supply and pricing pressure may compress immunoglobulin margins